Table 3.

Predictive factors of herpes zoster development in our cohort of patients with rheumatoid arthritis.

	HR (95% CI)	p
Age (years) (mean ± SD)	1.02 (0.99–1.05)	0.21
Time of evolution of RA (months) (mean ± SD)	1.002 (0.99–1.005)	0.31
Women, n (%)	1.31 (0.50–3.42)	0.58
Active smokers, n (%)	0.90 (0.43–1.90)	0.79
Hypertension, n (%)	2.25 (1.09–4.68)	0.029
Diabetes mellitus, n (%)	1.70 (0.70–4.17)	0.24
Dyslipidemia, n (%)	1.50 (0.73–3.08)	0.27
Positive RF, n (%)	0.96 (0.46–1.97)	0.91
Positive anti-CCP, n (%)	0.67 (0.33–1.38)	0.28
Erosions, n (%)	0.86 (0.40–1.85)	0.71
Subcutaneous nodules, n (%)	0.53 (0.07–3.92)	0.54
Interstitial lung disease, n (%)	2.10 (0.64–6.94)	0.22
Sjögren syndrome, n (%)	0.62 (0.08–4.52)	0.63
Number of conventional synthetic DMARDs (not concomitant)
Methotrexate	0.77 (0.29–2.06)	0.60
Leflunomide	1.33 (0.67–2.66)	0.42
Sulfasalazine	1.08 (0.46–2.51)	0.87
Gold salts	1.04 (0.32.3.44)	0.95
Biological DMARDs, n (%)
Any anti-TNF	1.12 (0.51–2.47)	0.78
Adalimumab	1.21 (0.59–2.50)	0.60
Etanercept	2.04 (0.99–4.18)	0.05
Infliximab	1.88 (0.72–4.90)	0.20
Golimumab	1.05 (0.32–3.48)	0.93
Certolizumab Pegol	0.98 (0.13–7.18)	0.98
Tocilizumab	1.55 (0.75–3.17)	0.23
Rituximab	1.94 (0.88–4.22)	0.99
Abatacept	1.46 (0.59–3.57)	0.41
Sarilumab	3.90 (0.53–28.62)	0.18
JAK inhibitors	1.46 (0.56–3.82)	0.44
Tofacitinib	1.34 (0.32–5.64)	0.69
Baricitinib	0.73 (0.17–3.07)	0.67
Upadacitinib	4.14 (0.56–30.59)	0.16

Abbreviations (in alphabetical order): anti-CCP: anti-cyclic citrullinated protein antibodies; CI: confidence interval; DMARDs: disease-modifying anti-rheumatic drugs; HR: hazard ratio; JAK: Janus kinase; N (n): number; RF: rheumatoid factor; TNF: tumor necrosis factor; and SD: standard deviation.